卡普拉西祖马布在狼相关的血栓性血栓性缺血性紫外线 (TTP):导航自身免疫和微血管病变
Arathi Kulkarni1, Kiera Vaughn1, Curtis Lacy2
1Internal Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Cureus
|December 30, 2025
概括
系统性红斑狼 (SLE) 可以导致血栓性血栓细胞性紫外线 (TTP). 卡普拉奇祖马布有效地治疗了一名患有狼相关的TTP的患者,该患者的血小板狭窄症迅速改善.
科学领域:
- 血液学 血液学 血液学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 血栓性血栓塞性紫外线 (TTP) 是系统性红斑狼 (SLE) 的罕见,严重并发症.
- 在SLE中TTP可能源于ADAMTS13缺乏或补充激活.
- 免疫介导的TTP呈现出微血管病性血液溶解性贫血和血栓细胞减小.
研究的目的:
- 报告一例成功治疗狼相关免疫TTP的卡普拉齐祖马布病例.
- 审查在SLE患者中管理TTP的诊断和治疗挑战.
主要方法:
- 一个55岁的患有Sjögren病和新发性SLE的女性的临床病例介绍.
- 诊断通过临床表现,实验室检测 (严重贫血,血栓缩,ADAMTS13活性低) 和免疫学发现得到证实.
- 治疗包括等离子体,皮质类固醇,修复剂和卡普拉西祖马布.
主要成果:
- 患者表现出与免疫介导的TTP一致的症状,并减少了ADAMTS13活性.
- 最初用血酶,皮质类固醇和修复剂治疗显示部分反应.
- 添加卡普拉西祖马布导致了快速和持续的血小板缺血的改善.
结论:
- 卡普拉西祖马布有效治疗与SLE相关的免疫媒介TTP.
- 这一案例强调了对狼相关的TTP及时诊断和多模式治疗的重要性.
- 需要进一步的研究来探索caplacizumab在SLE中TTP管理中的作用.
相关概念视频
Autoimmune Disorders
1.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
1.4K
Peripheral Artery Disease III: Interprofessional Care
215
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
215
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447


